Cover Image
市場調查報告書

人類乳突病毒(HPV)相關的癌症:開發平台分析

Human Papillomavirus (HPV) Associated Cancer - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 255958
出版日期 內容資訊 英文 172 Pages
訂單完成後即時交付
價格
Back to Top
人類乳突病毒(HPV)相關的癌症:開發平台分析 Human Papillomavirus (HPV) Associated Cancer - Pipeline Review, H2 2016
出版日期: 2016年09月14日 內容資訊: 英文 172 Pages
簡介

本報告提供全球人類乳突病毒(HPV)相關的癌症治療藥開發趨勢調查,提供您開發中產品的各開發階段比較分析,藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,以及這個部門的最新趨勢,主要企業評估等資訊。

簡介

  • 調查範圍

HPV相關的癌症概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

企業開發中的治療藥

大學/機關研究中的治療藥

開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關研究中的產品

治療藥的開發企業

  • 3SBio Inc.
  • Abivax
  • Admedus Ltd
  • Antigen Express, Inc.
  • Bionor Pharma ASA
  • Cancer Therapeutics CRC Pty Ltd
  • Etubics Corporation
  • EyeGene, Inc.
  • Formune S.L.
  • Genexine, Inc.
  • iBio, Inc.
  • Inovio Pharmaceuticals, Inc.
  • MedImmune, LLC
  • Merck & Co., Inc.
  • Novartis AG
  • Onconova Therapeutics, Inc.
  • Prima BioMed Ltd.
  • Profectus BioSciences, Inc.
  • Redbiotec AG
  • Sirnaomics, Inc.
  • Theravectys S.A.
  • Transgene SA
  • Vaccibody AS
  • Virometix AG
  • ViroStatics, srl

治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • ABX-318
  • AEH-10p
  • alpelisib
  • Antibodies to Target E6 for HPV Associated Cancer
  • Antibodies to Target E7 for HPV Associated Cancer
  • Cell Therapy to Target HPV-16 E6 Protein for Papillomavirus Associated Cancers
  • durvalumab + tremelimumab
  • EDA-HPVE7
  • EG-HPV
  • Gene Therapy for Papillomavirus Associated Cervical Carcinoma
  • GX-188E
  • HPV Vaccine
  • human papillomavirus (7-valent) vaccine
  • human papillomavirus (9-valent) vaccine
  • human papillomavirus Serotype 16 vaccine
  • human papillomavirus vaccine
  • human papillomavirus vaccine
  • human papillomavirus vaccine types 6, 11, 16, 18 biosimilar
  • INO-3106
  • INO-3112
  • Peptide to Inhibit HPV E6 Protein for HPV Associated Cancer
  • RBT-201
  • rigosertib sodium
  • Small Molecule to Inhibit CDK9 for HPV Associated Cancers and Warts
  • Small Molecules to Inhibit Ubiquitin E3 Ligase E6AP for Cancer
  • SSS-08
  • STP-909
  • STP-911
  • TG-4001
  • Vacc-HPV
  • Vaccine for HPV Associated Cancer
  • Vaccine for HPV Associated Cancers
  • Vaccine for HPV Associated Cancers
  • Vaccine for HPV Associated Head and Neck Cancer
  • Vaccine for HPV Associated Skin Cancer 1
  • Vaccines for HPV Associated Cervical Cancer
  • VB-1016
  • Vicoryx

最近的開發平台趨勢

暫停中的計劃

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8460IDB

Summary

Global Markets Direct's, 'Human papillomavirus (HPV) Associated Cancer - Pipeline Review, H2 2016', provides an overview of the Human papillomavirus (HPV) Associated Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Human papillomavirus (HPV) Associated Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Human papillomavirus (HPV) Associated Cancer and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Human papillomavirus (HPV) Associated Cancer
  • The report reviews pipeline therapeutics for Human papillomavirus (HPV) Associated Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Human papillomavirus (HPV) Associated Cancer therapeutics and enlists all their major and minor projects
  • The report assesses Human papillomavirus (HPV) Associated Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Human papillomavirus (HPV) Associated Cancer

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Human papillomavirus (HPV) Associated Cancer
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Human papillomavirus (HPV) Associated Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Human Papillomavirus (HPV) Associated Cancer Overview
  • Therapeutics Development
    • Pipeline Products for Human Papillomavirus (HPV) Associated Cancer - Overview
    • Pipeline Products for Human Papillomavirus (HPV) Associated Cancer - Comparative Analysis
  • Human Papillomavirus (HPV) Associated Cancer - Therapeutics under Development by Companies
  • Human Papillomavirus (HPV) Associated Cancer - Therapeutics under Investigation by Universities/Institutes
  • Human Papillomavirus (HPV) Associated Cancer - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Human Papillomavirus (HPV) Associated Cancer - Products under Development by Companies
  • Human Papillomavirus (HPV) Associated Cancer - Products under Investigation by Universities/Institutes
  • Human Papillomavirus (HPV) Associated Cancer - Companies Involved in Therapeutics Development
    • Admedus Ltd
    • Advaxis, Inc.
    • Antigen Express, Inc.
    • Bionor Pharma ASA
    • BioNTech AG
    • Cancer Research Technology Limited
    • Cell Medica Limited
    • Etubics Corporation
    • EyeGene, Inc.
    • Formune S.L.
    • Genexine, Inc.
    • Genticel S.A.
    • iBio, Inc.
    • Immunovaccine, Inc.
    • Inovio Pharmaceuticals, Inc.
    • Inthera Bioscience AG
    • Johnson & Johnson
    • Karyopharm Therapeutics, Inc.
    • Kite Pharma, Inc.
    • MedImmune, LLC
    • Novartis AG
    • Onconova Therapeutics, Inc.
    • Oryx GmbH & Co. KG
    • Profectus BioSciences, Inc.
    • Selecta Biosciences, Inc.
    • Shantha Biotechnics Limited
    • Sirnaomics, Inc.
    • Theravectys SA
    • THEVAX Genetics Vaccine USA Inc
    • Tomegavax, Inc.
    • Transgene SA
    • UbiVac, LLC
    • Vaccibody AS
    • Vault Pharma Inc.
    • Virometix AG
    • ViroStatics srl
    • VLPbio
  • Human Papillomavirus (HPV) Associated Cancer - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • ABI-1968 - Drug Profile
    • AEH-10p - Drug Profile
    • alpelisib - Drug Profile
    • Antibodies to Target E6 for HPV Associated Cancer - Drug Profile
    • Antibodies to Target E7 for HPV Associated Cancer - Drug Profile
    • BVAC-C - Drug Profile
    • Cellular Immunotherapy for HPV Associated Cancers - Drug Profile
    • Cellular Immunotherapy to Target HPV-16 E6 Protein for Cancer - Drug Profile
    • Cellular Immunotherapy to Target HPV-16 E7 Protein for Head and Neck Cancer and Cervical Cancer - Drug Profile
    • CerviVax - Drug Profile
    • CMD-004 - Drug Profile
    • DPV-001 - Drug Profile
    • DPXE-7 - Drug Profile
    • EDA-HPVE7 - Drug Profile
    • EG-HPV - Drug Profile
    • Enzymes to Inhibit HPV E7 for Human Papillomavirus Related Cervical Cancer - Drug Profile
    • ETBX-041 - Drug Profile
    • GTL-001 - Drug Profile
    • GTL-002 - Drug Profile
    • GX-188E - Drug Profile
    • human papillomavirus (7-valent) vaccine - Drug Profile
    • human papillomavirus [Serotype 16] vaccine - Drug Profile
    • human papillomavirus [serotypes 16] vaccine - Drug Profile
    • human papillomavirus vaccine - Drug Profile
    • human papillomavirus vaccine - Drug Profile
    • human papillomavirus vaccine - Drug Profile
    • human papillomavirus vaccine [types 6, 11, 16, 18] biosimilar - Drug Profile
    • INO-3106 - Drug Profile
    • INO-3112 - Drug Profile
    • Lm-LLO-ISG15 - Drug Profile
    • LN-145 - Drug Profile
    • Monoclonal Antibody to Target E6 and E7 Proteins for Oncology - Drug Profile
    • NIT-02 - Drug Profile
    • NP-001 - Drug Profile
    • PVX-01 - Drug Profile
    • Recombinant Vector Vaccine to Target E7 for HPV Associated Cancers - Drug Profile
    • Recombinant Vector Vaccine to Target E7 for HPV Associated Cervical Intraepithelial Neoplasia - Drug Profile
    • rigosertib sodium - Drug Profile
    • sdCMV-002 - Drug Profile
    • SEL-701 - Drug Profile
    • Small Molecule to Inhibit CDK4, CDK6 and CDK9 for HPV Associated Cancers - Drug Profile
    • Small Molecules for Solid Tumors and HPV Associated Cancer - Drug Profile
    • STP-909 - Drug Profile
    • Subunit Vaccine for HPV Associated Cervical Cancer - Drug Profile
    • Synthetic Peptide to Inhibit HPV E6 Protein for HPV Associated Cancer - Drug Profile
    • TA-CIN - Drug Profile
    • TG-4001 - Drug Profile
    • TVGV-1 - Drug Profile
    • Vacc-HPV - Drug Profile
    • Vaccine for HIV and HPV Associated Cancer - Drug Profile
    • Vaccine for HPV Associated Cancer - Drug Profile
    • Vaccine for HPV Associated Cancers - Drug Profile
    • Vaccine for HPV Associated Cervical Cancer - Drug Profile
    • Vaccine for HPV Associated Cervical Cancer - Drug Profile
    • Vaccine for HPV Associated Cervical Cancer - Drug Profile
    • Vaccine for HPV Associated Skin Cancer - Drug Profile
    • Vaccine for Human papillomavirus Associated Cervical Cancer - Drug Profile
    • VB-1016 - Drug Profile
    • verdinexor - Drug Profile
    • VGX-3100 - Drug Profile
    • Vicoryx - Drug Profile
    • VMT-2 - Drug Profile
    • VPI-241 - Drug Profile
    • Vvax-001 - Drug Profile
  • Human Papillomavirus (HPV) Associated Cancer - Dormant Projects
  • Human Papillomavirus (HPV) Associated Cancer - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Human Papillomavirus (HPV) Associated Cancer, H2 2016
  • Number of Products under Development for Human Papillomavirus (HPV) Associated Cancer - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Human Papillomavirus (HPV) Associated Cancer - Pipeline by Admedus Ltd, H2 2016
  • Human Papillomavirus (HPV) Associated Cancer - Pipeline by Advaxis, Inc., H2 2016
  • Human Papillomavirus (HPV) Associated Cancer - Pipeline by Antigen Express, Inc., H2 2016
  • Human Papillomavirus (HPV) Associated Cancer - Pipeline by Bionor Pharma ASA, H2 2016
  • Human Papillomavirus (HPV) Associated Cancer - Pipeline by BioNTech AG, H2 2016
  • Human Papillomavirus (HPV) Associated Cancer - Pipeline by Cancer Research Technology Limited, H2 2016
  • Human Papillomavirus (HPV) Associated Cancer - Pipeline by Cell Medica Limited, H2 2016
  • Human Papillomavirus (HPV) Associated Cancer - Pipeline by Etubics Corporation, H2 2016
  • Human Papillomavirus (HPV) Associated Cancer - Pipeline by EyeGene, Inc., H2 2016
  • Human Papillomavirus (HPV) Associated Cancer - Pipeline by Formune S.L., H2 2016
  • Human Papillomavirus (HPV) Associated Cancer - Pipeline by Genexine, Inc., H2 2016
  • Human Papillomavirus (HPV) Associated Cancer - Pipeline by Genticel S.A., H2 2016
  • Human Papillomavirus (HPV) Associated Cancer - Pipeline by iBio, Inc., H2 2016
  • Human Papillomavirus (HPV) Associated Cancer - Pipeline by Immunovaccine, Inc., H2 2016
  • Human Papillomavirus (HPV) Associated Cancer - Pipeline by Inovio Pharmaceuticals, Inc., H2 2016
  • Human Papillomavirus (HPV) Associated Cancer - Pipeline by Inthera Bioscience AG, H2 2016
  • Human Papillomavirus (HPV) Associated Cancer - Pipeline by Johnson & Johnson, H2 2016
  • Human Papillomavirus (HPV) Associated Cancer - Pipeline by Karyopharm Therapeutics, Inc., H2 2016
  • Human Papillomavirus (HPV) Associated Cancer - Pipeline by Kite Pharma, Inc., H2 2016
  • Human Papillomavirus (HPV) Associated Cancer - Pipeline by MedImmune, LLC, H2 2016
  • Human Papillomavirus (HPV) Associated Cancer - Pipeline by Novartis AG, H2 2016
  • Human Papillomavirus (HPV) Associated Cancer - Pipeline by Onconova Therapeutics, Inc., H2 2016
  • Human Papillomavirus (HPV) Associated Cancer - Pipeline by Oryx GmbH & Co. KG, H2 2016
  • Human Papillomavirus (HPV) Associated Cancer - Pipeline by Profectus BioSciences, Inc., H2 2016
  • Human Papillomavirus (HPV) Associated Cancer - Pipeline by Selecta Biosciences, Inc., H2 2016
  • Human Papillomavirus (HPV) Associated Cancer - Pipeline by Shantha Biotechnics Limited, H2 2016
  • Human Papillomavirus (HPV) Associated Cancer - Pipeline by Sirnaomics, Inc., H2 2016
  • Human Papillomavirus (HPV) Associated Cancer - Pipeline by Theravectys SA, H2 2016
  • Human Papillomavirus (HPV) Associated Cancer - Pipeline by THEVAX Genetics Vaccine USA Inc, H2 2016
  • Human Papillomavirus (HPV) Associated Cancer - Pipeline by Tomegavax, Inc., H2 2016
  • Human Papillomavirus (HPV) Associated Cancer - Pipeline by Transgene SA, H2 2016
  • Human Papillomavirus (HPV) Associated Cancer - Pipeline by UbiVac, LLC, H2 2016
  • Human Papillomavirus (HPV) Associated Cancer - Pipeline by Vaccibody AS, H2 2016
  • Human Papillomavirus (HPV) Associated Cancer - Pipeline by Vault Pharma Inc., H2 2016
  • Human Papillomavirus (HPV) Associated Cancer - Pipeline by Virometix AG, H2 2016
  • Human Papillomavirus (HPV) Associated Cancer - Pipeline by ViroStatics srl, H2 2016
  • Human Papillomavirus (HPV) Associated Cancer - Pipeline by VLPbio, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Human Papillomavirus (HPV) Associated Cancer - Dormant Projects, H2 2016
  • Human Papillomavirus (HPV) Associated Cancer - Dormant Projects (Contd..1), H2 2016

List of Figures

  • Number of Products under Development for Human Papillomavirus (HPV) Associated Cancer, H2 2016
  • Number of Products under Development for Human Papillomavirus (HPV) Associated Cancer - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Top 10 Routes of Administration, H2 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top